Drug Profile
AEOL 11114
Alternative Names: AEOL 11114B; AEOL11114Latest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator National Jewish Medical and Research Center; University of Colorado at Anschutz Medical Campus
- Class Antiparkinsonians; Glyoxylates; Metalloporphyrins; Porphyrins
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (PO)
- 31 Mar 2016 Aeolus receives patent allowance for AAEOL 11114 in Japan prior to March 2016
- 02 Nov 2015 AEOL 11114 licensed to Aeolus worldwide for the treatment of Parkinson's disease